Philip N. Newsome - Concepedia

Author

Philip N. Newsome

Also Known As

E Barnes, George Boon-Bee Goh, J. M. Navarrete, JM Navarrete, Jonathan J. Deeks, Michael Manns, Mike N. Badminton, Moritz Schneider, Newsome, P, Newsome, PN

561

Publications

46.1K

Citations

H-Index

139

Concepts

All Affiliations

University of Birmingham National Institute for Health Research University Hospitals Birmingham NHS Foundation Trust NIHR Birmingham Biomedical Research Centre NIHR Birmingham Liver Biomedical Research Unit

About

Philip N. Newsome is an author at University of Birmingham specializing in medicine, hepatology, and liver physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	44	14.2K
2	Health Sciences	15	15	6K
3	Public Health	7	7	544
4	Engineering	1	1	28
5	Natural Sciences	1	1	105

Philip N. Newsome

130

Publications

23.2K

Citations

H-Index

Page 1

	Year	Citations
A multisociety Delphi consensus statement on new fatty liver disease nomenclature Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Hepatology Evidence-based MedicinePathologyFatty Liver DiseaseObesityMetabolic Syndrome	2023	2.5K
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study Matthew J. Armstrong, Piers Gaunt, Guruprasad P. Aithal, The Lancet Placebo-controlled Phase 2Liraglutide SafetyHepatologyNon-alcoholic SteatohepatitisHepatotoxicity	2015	2K
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi, New England Journal of Medicine	2020	1.7K
Resolving the fibrotic niche of human liver cirrhosis at single-cell level Prakash Ramachandran, Ross Dobie, John R. Wilson‐Kanamori, Nature Single-cell LevelFibrosisHepatologyLiver PhysiologyPathology	2019	1.6K
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy, New England Journal of Medicine	2024	1.4K
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Peter Eddowes, M. Sasso, Michael Allison, Gastroenterology HepatologyLiver Stiffness MeasurementNonalcoholic Fatty Liver DiseaseLiver PhysiologyAssessing Steatosis	2019	1.3K
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study Philip N. Newsome, M. Sasso, Jonathan J Deeks, The Lancet. Gastroenterology & hepatology	2020	729
Immunomodulation By Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells S Witte, Franka Luk, Jesús María Sierra-Párraga, Stem Cells	2018	502
Guidelines on the management of abnormal liver blood tests Philip N. Newsome, R Cramb, Suzanne Davison, Gut Blood TestsDiagnosisPathologyGastroenterologyFatty Liver Disease	2017	497

Page 1